Kazuko Fukuda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kazuko Fukuda has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Haruki Kume
National Clinical Database Steering Committee of Japanese Urological Association Tokyo Japan
1 shared publication - Kazuyoshi Shigehara
Department of Integrative Cancer Therapy and Urology Kanazawa University Graduate School of Medical Science Kanazawa Ishikawa Japan
1 shared publication - Motofumi Suzuki
Department of Urology, Tokyo Metropolitan Bokutoh Hospital, Tokyo 130-8575, Japan
1 shared publication - Tadaichi Kitamura
Japanese Foundation of Sexual Health Medicine, Tokyo 113-0034, Japan
1 shared publication - Taeko Matsuyama
Department of Nursing, Tachikawa Faculty of Nursing, Tokyo Healthcare University, Tachikawa 190-8590, Japan
1 shared publication
Latest Publications
- Open Access
Prevalence of Human Papillomavirus Types 16/18 and Effect of Vaccination among Japanese Female General Citizens in the Vaccine Crisis Era
The Japanese government withdrew its recommendation for human papillomavirus (HPV) vaccination in June 2013 and resumed it in April 2022. This period is known as the vaccine crisis in Japan. This study aimed to elucidate the prevalence and genotype distribution of HPV among Japanese female citizens, and the effect of vaccination against HPV-16/18 in the era of the vaccine crisis. We recruited Japanese female citizens and asked them to provide self-collected samples from the vaginal wall using cotton swabs for HPV genotyping. Furthermore, we collected the participants’ characteristics, including lifestyle and experience of vaccination against HPV, to determine the significant association with HPV infection. HPV-16/18 positivity was found in 5.6% (115/2044) of participants. The highest vaccination rate was observed in the age group of 20–24 years (60.6%), whereas the lowest HPV-16/18 positivity was observed in the age group of 45–49 years (2.8%), followed by the age group of 20–24 years (4.0%). Experience with HPV vaccination significantly reduced the risk of HPV-16/18 infection (adjusted odds ratio, 0.047; 95% confidence interval, 0.011–0.196). Vaccinated women were much less likely to be infected by HPV-16/18, regardless of the HPV vaccine type or the vaccination dose.
Open AccessPrevalence of Human Papillomavirus Types 16/18 and Effect of Vaccination among Japanese Female General Citizens in the Vaccine Crisis Era
The Japanese government withdrew its recommendation for human papillomavirus (HPV) vaccination in June 2013 and resumed it in April 2022. This period is known as the vaccine crisis in Japan. This study aimed to elucidate the prevalence and genotype distribution of HPV among Japanese female citizens, and the effect of vaccination against HPV-16/18 in the era of the vaccine crisis. We recruited Japanese female citizens and asked them to provide self-collected samples from the vaginal wall using cotton swabs for HPV genotyping. Furthermore, we collected the participants’ characteristics, including lifestyle and experience of vaccination against HPV, to determine the significant association with HPV infection. HPV-16/18 positivity was found in 5.6% (115/2044) of participants. The highest vaccination rate was observed in the age group of 20–24 years (60.6%), whereas the lowest HPV-16/18 positivity was observed in the age group of 45–49 years (2.8%), followed by the age group of 20–24 years (4.0%). Experience with HPV vaccination significantly reduced the risk of HPV-16/18 infection (adjusted odds ratio, 0.047; 95% confidence interval, 0.011–0.196). Vaccinated women were much less likely to be infected by HPV-16/18, regardless of the HPV vaccine type or the vaccination dose.